

ALC-PROOF-CJC-IPA-10-46 · Rev 1

Catalog reference: cjc-ipa-10

Search code: ALC-PROOF-CJC-IPA-10-46

Received: 2026-09-28

Analyzed: 2026-09-29

Reported: 2026-09-30

Lot: SYN-00046

Sample Summary

Product: CJC-1295 without DAC +
Ipamorelin – 10 mg

Principal peak purity: 98.86 % (area)

Identity evidence: Not established by this report

Net content: 10.249 mg

Molecular formula: Component formulas in
supporting references

Neutral mass: No single molecular mass for a
blend

Appearance: Lyophilized material

Chemical reference: Component references in
supporting notes

Component	Label claim	Measured content
CJC-1295 without DAC	5 mg	Not measured
Ipamorelin	5 mg	Not measured

Analytical Results


Review required

Profile profile-cjc-ipa-10 v1.

Determination / method	Result	Specification	Decision
Principal peak purity HPLC-01 · area basis Peak area percent. This is not a mass fraction.	98.86 % U = 0.08 %, k = 2	98 to 100 %	Pass simple
Net content QNT-01 · mass basis Specification applies to the declared label claim.	10.249 mg U = 0.15 mg, k = 2	9 to 11 mg	Pass guard-band

Methods: Quantitative assay; RP-HPLC with UV detection. Conditions, limits and calculated checks are included in the supporting pages.

Chromatogram



Paul Gütse

Paul Gütse

Reviewed by

Evidence incomplete. Composition and component assay evidence must be resolved before issuance.


Scan report code

Local design proof
ALC-PROOF-CJC-IPA-10-46




alchemlabs.org

Results apply only to the submitted sample and the methods listed in this report. Only the listed methods are covered. This report does not establish sterility, endotoxin content, biological activity or suitability for clinical use.



Integrated peak	Area (detector unit x min)	Area %
Principal peak	280.76037	98.86
Early impurity	2.10909	0.74
Late impurity	1.13745	0.40



Calculated checks and system suitability			
Analysis check	Value	Configured criterion	Assessment
Principal peak purity	98.86 % area	Minimum 98; caution below 99	review
Assay relative to label claim	102.49 %	90 to 110	pass
Total integrated impurities	1.1431 % area	Maximum 2	pass
Largest integrated impurity	0.7426 % area	Maximum 1.5	pass
Retention time	8.61 min	8.61 +/- 0.2	pass
Principal peak width at half height	0.3111 min	0.3103 +/- 30%	pass
Theoretical plates	4242	Minimum 2000	pass
Resolution to Early impurity	3.294	Minimum 1.5	pass
Resolution to Late impurity	3.422	Minimum 1.5	pass
Tailing factor at 5% height	1.032	Maximum 2	pass
Principal signal to baseline noise	19712.4	Minimum 50	pass
Calibration R squared	0.999997	Minimum 0.995	pass
Independent QC bias	-0.121 %	Absolute maximum 5	pass
Calibration-derived content	10.249 mg	Agrees with reported content within uncertainty	informational

Assessment observations

WARNING · purity-caution

Purity is below the configured caution bar. Review impurity distribution.

WARNING · impurity-detected

Early impurity: 0.743% area meets the configured impurity reporting threshold 0.05%.

WARNING · impurity-detected

Late impurity: 0.401% area meets the configured impurity reporting threshold 0.05%.

ERROR · blend-area-purity

A single principal peak area cannot establish the purity or composition of a blend. Supply a dossier for each component.

ERROR · component-evidence

Component CJC-1295 without DAC requires its own assay and identity evidence.

ERROR · component-evidence

Component Ipamorelin requires its own assay and identity evidence.

Methods and decision rules

QNT-01 · Quantitative assay 1

Instrument: analytical balance

Calibration and replicate measurement. Expanded uncertainty uses $k = 2$.

Expanded measurement uncertainty uses a coverage factor of 2.

HPLC-01 · RP-HPLC with UV detection 1

Instrument: HPLC-UV

C18 column, 150 x 4.6 mm, 5 μ m; 0.1% formic acid in water/acetonitrile; 5 to 60% B over 15 min; 1.0 mL/min; 25 C; 214 nm; 10 μ L injection.

Trapezoidal integration against the declared baseline and windows.

Simple acceptance compares the result with the stated limits. Guard band acceptance requires the full expanded uncertainty interval to fall within the limits; overlap is indeterminate. A failed specification remains a reportable result.

Scope and observations

User supplied 5 + 5 mg. Confirm component identities and assay each separately.

Reference values apply to the named components separately, not the whole blend. Component ratios, chemical forms and identity require laboratory confirmation.

Component chemical reference properties

Reference component	Molecular formula	Neutral mass (Da)	Source
CJC-1295 without DAC	C152H252N44O42	3,365.89358	Cayman 32704 no-DAC product sheet
Ipamorelin	C38H49N9O5	711.38567	PubChem CID 9831659

Masses are calculated using the monoisotopic convention; they are not observed MS results.

CJC-1295 without DAC: Modified GRF(1-29), D-Ala2, C-terminal amide; no DAC. No-DAC peptide reference. The source supplies variable acetate salt; acetate is excluded. DAC-conjugated CJC has a different formula. Sample sequence and salt form are not confirmed. [PubChem CID 56841945 structure](#).

Ipamorelin: Neutral Ipamorelin peptide. Reference analyte formula; counterions and hydration excluded. Sample chemical form is not confirmed.

Only the listed methods are covered. This report does not establish sterility, endotoxin content, biological activity or suitability for clinical use.

Sample reference: Catalog identity and nominal content supplied by the client.

Chemical form: Chemical form and sequence require a laboratory reference.

Chemical reference: Component references in supporting notes

Prepared by: alchemlabs